Benefits
Fibrinolytic Activity
Nattokinase directly cleaves fibrin (the protein scaffold of blood clots) — distinct from anticoagulants (which prevent clot formation by inhibiting clotting factors) and antiplatelets (which prevent platelet aggregation). Activates endogenous tissue plasminogen activator (tPA) and degrades fibrin directly.
Blood Pressure Modest Reduction
Kim 2008 and RCTs showed nattokinase (2,000 FU/day) modestly reduced both systolic and diastolic blood pressure in pre/hypertensive adults vs placebo. Effect size ~5-6 mmHg systolic — clinically meaningful but modest.
Cardiovascular Risk Markers
Several trials show nattokinase reduces fibrinogen, factor VII, and factor VIII levels — plus may reduce LDL and triglycerides, raise HDL. Multi-mechanism cardiovascular support.
Deep Vein Thrombosis (DVT) Prevention (Theoretical)
trial showed nattokinase (2 capsules/day) reduced edema and DVT incidence vs placebo on long-haul flights. Mechanism plausible; sample size limited. Standard DVT prevention for high-risk patients remains anticoagulants and compression.
Long-COVID / Spike Protein Research (Emerging)
Recent in vitro research suggests nattokinase may degrade SARS-CoV-2 spike protein. Generated significant interest in long-COVID and post-vaccine spike protein clearance. Critical caveat: in vitro evidence; human clinical translation not established; do not use as substitute for evidence-based COVID treatments.
Mechanism of action
Direct Fibrin Cleavage
Nattokinase is a serine protease that directly cleaves fibrin into smaller fragments — same end result as endogenous plasmin. Distinct from anticoagulant drugs (which work upstream by inhibiting clotting factors).
tPA Activation
Nattokinase enhances production and activity of endogenous tissue plasminogen activator (tPA) — increasing physiological fibrinolytic capacity. Both direct (NK cleaves fibrin) and indirect (NK activates plasmin via tPA) mechanisms.
PAI-1 Inhibition
Nattokinase reduces plasminogen activator inhibitor-1 (PAI-1) — a fibrinolysis inhibitor. Lower PAI-1 = greater fibrinolytic activity. PAI-1 elevation associated with metabolic syndrome and CV risk.
Pleiotropic Cardiovascular Effects
Beyond fibrinolysis: BP reduction (mechanism unclear; possibly via ACE inhibition), modest lipid effects, reduced platelet aggregation. Multi-mechanism CV agent.
Clinical trials
Double-blind clinical trial of nattokinase (2,000 FU/day) vs placebo in 86 prehypertensive adults for 8 weeks.
86 prehypertensive adults.
Nattokinase reduced systolic BP by ~5.5 mmHg and diastolic BP by ~2.8 mmHg vs placebo. Modest but clinically meaningful effect. Subsequent trial confirmed similar magnitude.
Clinical trial of nattokinase + pycnogenol vs placebo for DVT prevention in 200 long-haul flight passengers.
200 high-risk flight passengers.
Nattokinase + pycnogenol group: 0% DVT incidence vs 5% in placebo group; significant edema reduction. Combined product limits attribution to nattokinase alone. Suggestive but not definitive.